Alcohol Addiction: Genetic Predictors of Treatment Success
Genetic predictors significantly influence treatment success for Alcohol Use Disorder (AUD). A new study spotlights how genetic variants impact the effectiveness of topiramate, a medication aimed at reducing heavy drinking. Researchers discovered that polygenic scores, reflecting cumulative genetic risk, can predict treatment outcomes. Patients with higher scores experienced greater benefits from topiramate. This research supports the potential of tailoring AUD treatments based on an individual’s genetic profile, opening doors to more effective and personalized strategies. While topiramate shows promise, especially in reducing heavy drinking days, treatment is underused, which News Directory 3 is working to change. Discover what comes next as scientists delve deeper into how genetics can revolutionize AUD treatment.
Genetic variants Influence Topiramate’s Effect on Alcohol Use Disorder
Updated may 30, 2025
A new study indicates that genetic variants associated with alcohol use disorder (AUD) can affect how well a medication works. The research suggests avenues for tailoring treatments based on a patient’s genetic makeup, potentially improving outcomes for those struggling with AUD and heavy drinking.
Despite its effectiveness, medication is underutilized in AUD treatment, with prescriptions given to only a small fraction of diagnosed patients. Topiramate, though not specifically approved for AUD, has shown promise in reducing heavy drinking and related problems in clinical trials.
Researchers from the University of Pennsylvania and Yale investigated whether genetic factors influence topiramate’s effectiveness. Thier work, published in Alcohol: Clinical and Experimental Research, explored whether polygenic scores—complete measures of genetic risk—could predict treatment outcomes.
The study involved data from 285 patients of European descent with AUD, all of whom underwent genetic testing and were treated with either topiramate or a placebo.
The team used large genetic databases to create polygenic scores reflecting the cumulative effect of multiple genetic variants linked to alcohol-related traits, including problematic alcohol use (PAU) and time to relapse (TR and THR).
Statistical analysis revealed that topiramate reduced both alcohol-related problems and heavy drinking compared to the placebo. The effect of topiramate on alcohol-related problems was significantly linked to polygenic scores for PAU, TR, and THR. Patients with higher scores experienced greater benefits from topiramate in reducing these problems.
These findings support the idea that genetic risk can moderate the effects of AUD medications, potentially enabling clinicians to match patients with the most effective treatments. The study also highlights the value of polygenic scores in investigating the interplay between genetics and medication in AUD treatment.
Because treatment response is complex, influenced by many genetic variants of small effect, polygenic scores may be especially useful in revealing moderating effects of genetic differences among patients.
What’s next
Future research should focus on larger studies to validate these findings and explore how polygenic scores can be integrated into clinical practice to personalize AUD treatment strategies.